Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study. / Larsen, Morten Kranker; Skov, Vibe; Kjær, Lasse; Eickhardt-Dalbøge, Christina Schjellerup; Knudsen, Trine Alma; Kristiansen, Marie Hvelplund; Sørensen, Anders Lindholm; Wienecke, Troels; Andersen, Morten; Ottesen, Johnny T.; Gudmand-Høyer, Johanne; Snyder, Jordan Andrew; Andersen, Mikkel Porsborg; Torp-Pedersen, Christian; Poulsen, Henrik Enghusen; Stiehl, Thomas; Hasselbalch, Hans Carl; Ellervik, Christina.
I: Blood Cancer Journal, Bind 14, Nr. 1, 28, 2024.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study
AU - Larsen, Morten Kranker
AU - Skov, Vibe
AU - Kjær, Lasse
AU - Eickhardt-Dalbøge, Christina Schjellerup
AU - Knudsen, Trine Alma
AU - Kristiansen, Marie Hvelplund
AU - Sørensen, Anders Lindholm
AU - Wienecke, Troels
AU - Andersen, Morten
AU - Ottesen, Johnny T.
AU - Gudmand-Høyer, Johanne
AU - Snyder, Jordan Andrew
AU - Andersen, Mikkel Porsborg
AU - Torp-Pedersen, Christian
AU - Poulsen, Henrik Enghusen
AU - Stiehl, Thomas
AU - Hasselbalch, Hans Carl
AU - Ellervik, Christina
N1 - Publisher Copyright: © 2024. The Author(s).
PY - 2024
Y1 - 2024
N2 - The neutrophil-to-lymphocyte ratio(NLR) is increased in chronic inflammation and myeloproliferative neoplasms (MPN). We hypothesize that NLR is associated with all-cause mortality and mortality by comorbidity burden in the general population and individuals with MPN. We included 835,430 individuals from The Danish General Suburban Population Study, general practitioners, and outpatient clinics. We investigated NLR on mortality stratified by prevalent and incident MPN, essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), comorbidity burden (CCI-score), and the Triple-A risk score using hazard ratio (HR) and 95% confidence interval (95%CI). NLR 1-1.9 was the reference level. During a median follow-up of 11.2 years, 197,802 deaths were recorded. All-cause mortality increased for a stepwise increasing NLR with a HR (95%CI) for NLR ≥ 6 of 2.06(2.03-2.09) for the whole population and 2.93(2.44-3.50) in prevalent MPN. ET, PV, and MF had a HR (95%CI) for NLR ≥ 2 of 2.14(1.71-2.69), 2.19(1.89-2.54), and 2.31(1.91-2.80). Results were similar for incident MPN. Mortality was higher for stepwise increasing NLR and CCI-score(pinteraction < 2×10-16), with a HR for NLR ≥ 6 of 2.23(2.17-2.29), 4.10(4.01-4.20), and 7.69(7.50-7.89), for CCI-score 0, 1-2, or ≥3. The Triple-A risk score demonstrated alignment with NLR. Increasing NLR and comorbidity burden were associated with lower survival in individuals without MPN but were even worse in prevalent and incident MPN, ET, PV, and MF.
AB - The neutrophil-to-lymphocyte ratio(NLR) is increased in chronic inflammation and myeloproliferative neoplasms (MPN). We hypothesize that NLR is associated with all-cause mortality and mortality by comorbidity burden in the general population and individuals with MPN. We included 835,430 individuals from The Danish General Suburban Population Study, general practitioners, and outpatient clinics. We investigated NLR on mortality stratified by prevalent and incident MPN, essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), comorbidity burden (CCI-score), and the Triple-A risk score using hazard ratio (HR) and 95% confidence interval (95%CI). NLR 1-1.9 was the reference level. During a median follow-up of 11.2 years, 197,802 deaths were recorded. All-cause mortality increased for a stepwise increasing NLR with a HR (95%CI) for NLR ≥ 6 of 2.06(2.03-2.09) for the whole population and 2.93(2.44-3.50) in prevalent MPN. ET, PV, and MF had a HR (95%CI) for NLR ≥ 2 of 2.14(1.71-2.69), 2.19(1.89-2.54), and 2.31(1.91-2.80). Results were similar for incident MPN. Mortality was higher for stepwise increasing NLR and CCI-score(pinteraction < 2×10-16), with a HR for NLR ≥ 6 of 2.23(2.17-2.29), 4.10(4.01-4.20), and 7.69(7.50-7.89), for CCI-score 0, 1-2, or ≥3. The Triple-A risk score demonstrated alignment with NLR. Increasing NLR and comorbidity burden were associated with lower survival in individuals without MPN but were even worse in prevalent and incident MPN, ET, PV, and MF.
U2 - 10.1038/s41408-024-00994-z
DO - 10.1038/s41408-024-00994-z
M3 - Journal article
C2 - 38331919
AN - SCOPUS:85184733321
VL - 14
JO - Blood Cancer Journal
JF - Blood Cancer Journal
SN - 2044-5385
IS - 1
M1 - 28
ER -
ID: 383884156